Highlights von Donnerstagnachmittag und Freitagnachmittag

Gampenrieder, SP; 1. Post-SABCS 2013; 10.01.2014; Wien. 2014.

Das triple-negative Mammakarzinom: eine therapeutische Herausforderung

Gampenrieder, SP; ÖGHO Frühjahrstagung; 11.04.2014; Innsbruck. 2014.

T-DM1

GAMPENRIEDER, SP; GREIL, R; MARTH, C; PETRU, E; RINNERTHALER, G; STEGER, GG ArzneimittelPROFIL T-DM1, Juli 2014. 2014.

The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by „on-demand“ addition of plerixafor to granulocyte-colony-stimulating factor.

Girbl, T; Lunzer, V; Greil, R; Namberger, K; Hartmann, TN TRANSFUSION. 2014; 54(9): 2325-2335.

Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).

Kocher, F; Pircher, A; Mohn-Staudner, A; Romeder, F; Duller, W; Steinmaurer, M; Eckmayr, J; Schmid, T; Hilbe, W; Fiegl, M; Greil, R LUNG CANCER. 2014; 85(3): 395-400.

Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials.

Goede, V; Cramer, P; Busch, R; Bergmann, M; Stauch, M; Hopfinger, G; Stilgenbauer, S; Doehner, H; Westermann, A; Wendtner, CM; Eichhorst, B; Hallek, M; Haematologica. 2014; 99(6): 1095-1100.

Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives

Hohla, F; Winder, T; Greil, R; Rick, FG; Block, NL; Schally, AV WORLD J GASTROENTERO. 2014; 20(20): 6102-6112.

A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).

Hutterer, M; Nowosielski, M; Haybaeck, J; Embacher, S; Stockhammer, F; Gotwald, T; Holzner, B; Capper, D; Preusser, M; Marosi, C; Oberndorfer, S; Moik, M; Buchroithner, J; Seiz, M; Tuettenberg, J; Herrlinger, U; Wick, A; Vajkoczy, P; Stockhammer, G; Neuro Oncol. 2014; 16(1):9-102

Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1.

Heitzer, E; Artl, M; Filipits, M; Resel, M; Graf, R; Weißenbacher, B; Lax, S; Gnant, M; Wrba, F; Greil, R; Dietze, O; Hofbauer, F; Böhm, G; Höfler, G; Samonigg, H; Schaberl-Moser, R; Balic, M; Dandachi, N; Mod Pathol. 2014; 27(6): 906-915.

Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases.

Berghoff, AS; Ilhan-Mutlu, A; Wöhrer, A; Hackl, M; Widhalm, G; Hainfellner, JA; Dieckmann, K; Melchardt, T; Dome, B; Heinzl, H; Birner, P; Preusser, M; Strahlenther Onkol. 2014; 190(7):676-685